We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Molecular Makeup Uncovered in New Form of Cancer

By LabMedica International staff writers
Posted on 25 Jun 2014
Print article
Image: The 3730xl DNA Analyzer (Photo courtesy of Applied Biosystems).
Image: The 3730xl DNA Analyzer (Photo courtesy of Applied Biosystems).
The molecular signature and genetic structure has been revealed of a new form of cancer that begins in the nose and is called biphenotypic sinonasal sarcoma (SNS).

The cancer, that appears to be most common in women, starts in the nose and can spread to the rest of the face, meaning the patient will need disfiguring surgery in order to survive, but by uncovering the molecular makeup of the tumor it was found that many existing cancer drugs that could be used to treat it.

A team of scientists from the Mayo Clinic (Rochester, MN, USA) retrieved formalin-fixed, paraffin-embedded tumor blocks and histological sections of SNS biopsied or resected between 1956 and 2013 for 25 tumors, including a second sample that was also characterized at the cytogenetic level. A frozen tumor sample was obtained from a single specimen characterized at the cytogenetic level. Formalin-fixed, paraffin-embedded material from 145 nonrelated tumors and normal tissues was also retrieved.

Transcriptome sequencing was performed on extracted ribonucleic acid (RNA), and the concentration was measured using a Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA, USA). Paired-end 50-base transcriptome sequencing was performed using a HiSeq 2000 sequencer (Illumina, San Diego, CA, USA). Real-time polymerase chain reaction were carried out on extracted RNA and sequenced with a 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA, USA). Other techniques including immunoblotting and immunofluorescence, luciferase assays immunohistochemistry, and fluorescence based in situ hybridization (FISH), were also used.

The scientists discovered a recurrent chromosomal translocation in SNS, t(2;4)(q35;q31.1), resulting in a paired box 3- mastermind-like 3 (PAX3-MAML3) fusion protein that is a potent transcriptional activator of PAX3 response elements. FISH and RT-PCR studies confirmed rearrangement of the PAX3 locus in 24 of 25 SNS tumors (96%) and identified the PAX3-MAML3 fusion gene in 19 of these tumors (79%). Five of the remaining SNS tumors exhibited rearrangement of the PAX3 locus without MAML3 involvement, and a single tumor showed rearrangement of the MAML3 locus without PAX3 involvement. They did not detect the PAX3-MAML3 fusion in 118 other tumors, including rhabdomyosarcomas, melanomas, and benign and malignant nerve sheath tumors or in 18 normal tissues, including 13 normal sinonasal tissues.

André M Oliveira, MD, the senior author of the study said, “It's unusual that a condition or disease is recognized, subsequently studied in numerous patients, and then genetically characterized all at one place. Usually these things happen over a longer period of time and involve separate investigators and institutions. Because of Mayo's network of experts, patient referrals, electronic records, biorepositories and research scientists, it all happened here. And this is only the tip of the iceberg. Who knows what is in our repositories waiting to be discovered?” The study was published on May 25, 2014, in the journal Nature Genetics.

Related Links:

Mayo Clinic 
Life Technologies
Applied Biosystems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.